Safety and efficacy of Jujadokseo-hwan for memory deficit (amnesia) in mild neurocognitive disorder: A protocol for randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial

• Published in: Medicine (Baltimore) Vol. 99; no. 8; p. e19231
• Main Authors: Jeong, Jin-Hyung, Lee, Ji-Yoon, Kim, Ju-Yeon, Seo, Young-Kyung, Kang, Wee-Chang, Kang, Hyung-Won, Park, So-Jung, Jang, Hye-Kyoung, Park, Yang-Chun, Jung, In Chul
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health 01.02.2020
• Subjects: Aged; Aged, 80 and over; Cognitive Dysfunction - drug therapy; Cost-Benefit Analysis; Double-Blind Method; Drugs, Chinese Herbal - adverse effects; Drugs, Chinese Herbal - economics; Drugs, Chinese Herbal - therapeutic use; Female; Humans; Male; Mental Status and Dementia Tests; Middle Aged; Multicenter Studies as Topic; Phytotherapy - methods; Quality of Life; Randomized Controlled Trials as Topic; Republic of Korea; Study Protocol Clinical Trial; Republic of Korea
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000019231

Mild neurocognitive disorder (mNCD) is one of the degenerative diseases that results in memory deficit, and can progress to dementia. The effectiveness of drug therapy for mNCD is still debatable, but treatment of this disease has important implications for postponing or preventing dementia. Jujadokseo-hwan (JDH) is a traditional herbal medicine formulation that exhibits improvement in cognitive abilities and neuroprotective effects. In this study, we will evaluate the safety and efficacy of JDH compared to placebo in mNCD patients. This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial. After obtaining informed consent from all participants and performing the screening process, the participants will be equally divided into an experimental group and a control group. Each participant will visit the trial center 7 times during the 12 weeks of intervention. The follow up study will be conducted 12 weeks after the intervention ends. The primary outcome is the variance in Seoul verbal learning test-elderly's version (SVLT-E) score from baseline to 12 weeks. Secondary outcomes include scores/values for the following variables: SVLT-E, Rey complex figure test, Digit span test, Korean-Boston naming test, calculation ability, controlled oral word association test, Korean-color word stroop test, digit symbol coding, Korean-trail making test-elderly's version, Korean version of mini mental state examination for dementia screening, euro-qol-5 dimension, pattern identifications tool for cognitive disorders, Korean version of Montreal cognitive assessment, Korean quality of life-Alzheimer disease, computerized tongue image analysis system, blood pressure pulse analyzer, bioelectrical impedance analyzer, wearable electroencephalogram device, functional near-infrared spectroscopy system, and cost analysis. This is the first trial evaluating the efficacy of JDH for mNCD. We expect this trial will provide strong support for wide use of JDH for mNCD and lead to further research on herbal medicine treatments for mNCD. KCT0003570 (Registered in Clinical Research Information Service of the Republic of Korea, https://cris.nih.go.kr/cris/search/search_result_st01.jsp?seq=12669).